Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CALCRL | Q16602 | 6/20 | 0.38 |
| ▸ | RAMP1 | O60894 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14098805 | 0.89 | MAPK1 (0.48) | ESR1ESR2PARP1PARP2MAPK1 | |
| SCHEMBL14498122 | 0.83 | DRD2 (0.42) | ESR1ESR2PARP1MAPK1DRD2 | |
| SCHEMBL14410236 | 0.83 | CALCRL (0.46) | HRH3PARP1PARP2CALCRLRAMP1 | |
| SCHEMBL14098835 | 0.82 | MAPK1 (0.46) | PARP1PARP2MAPK1CALCRLRAMP1 | |
| SCHEMBL14410229 | 0.77 | MAPK1 (0.48) | PARP1PARP2MAPK1CALCRLRAMP1 | |
| SCHEMBL1700420 | 0.75 | AHR (0.43) | HRH3CALCRLRAMP1DRD4 | |
| SCHEMBL4314542 | 0.74 | HRH3 (0.68) | ESR1ESR2HRH3PARP1PARP2 | |
| SCHEMBL4314546 | 0.74 | HRH3 (0.68) | ESR1ESR2HRH3PARP1PARP2 | |
| SCHEMBL14410174 | 0.74 | CALCRL (0.54) | PARP1PARP2CALCRLRAMP1 | |
| SCHEMBL13884873 | 0.72 | ESR1 (0.37) | ESR1ESR2DRD2DRD4CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7230001-B1 | Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208036-A1 | Arylalkanes, arylalkenes and aryl-azaalkanes, pharmaceutical compositions containing these compounds and processes for preparing them | ARRB1, NPY1R, ADRB3 | ESR1 2147/4885ESR2 1044/4885HRH3 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.